Diversify Advisory Services LLC Has $1.45 Million Position in Pfizer Inc. (NYSE:PFE)

Diversify Advisory Services LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 86.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 54,110 shares of the biopharmaceutical company's stock after selling 352,076 shares during the period. Diversify Advisory Services LLC's holdings in Pfizer were worth $1,446,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer during the fourth quarter worth $26,000. Gladius Capital Management LP raised its holdings in Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 38,015 shares during the period. Quarry LP bought a new position in Pfizer in the second quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new position in shares of Pfizer in the third quarter valued at approximately $35,000. Finally, Joseph Group Capital Management increased its position in shares of Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 771 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

PFE has been the subject of several recent research reports. UBS Group reduced their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Guggenheim lowered their price objective on shares of Pfizer from $35.00 to $33.00 and set a "buy" rating on the stock in a report on Wednesday, December 11th. Bank of America restated a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. StockNews.com lowered Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. Finally, Citigroup assumed coverage on Pfizer in a research note on Friday, October 25th. They issued a "neutral" rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and an average price target of $32.00.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the firm's stock in a transaction on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.06% of the stock is currently owned by insiders.

Pfizer Price Performance

Shares of PFE stock traded up $0.29 during trading on Tuesday, hitting $26.59. The company had a trading volume of 14,344,338 shares, compared to its average volume of 31,896,215. The firm has a market capitalization of $150.66 billion, a P/E ratio of 35.97, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock's 50-day moving average price is $26.08 and its 200 day moving average price is $27.98.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company's revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.17) EPS. Equities analysts expect that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.47%. Pfizer's payout ratio is presently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.